跳至主要内容
临床试验/NCT05442203
NCT05442203进行中(未招募)不适用

Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease

Tempus AI6 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2022年9月7日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
Tempus AI
入组人数
1,000
试验地点
6
主要终点
Positive-predictive value (PPV) of the SHD device at six months

研究概览

简要总结

Atrial fibrillation is an abnormal beating of the heart that can lead to stroke or heart failure. Structural heart diseases are conditions that affect the heart valves or heart muscle and can cause permanent heart damage if left untreated. Sometimes people have atrial fibrillation or structural heart disease and do not know it. The purpose of this study is to evaluate two devices that can predict who has or may develop atrial fibrillation or structural heart disease based on the results of an electrocardiogram.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Retrospective Phase:
  • Adults aged 40 or older.
  • At least 1 ECG obtained during routine clinical care.
  • Prospective Phase:
  • AF Cohort:
  • Adults aged 65 or older at the time of ECG.
  • ECG obtained as part of a clinical care.
  • Patient is able to identify a licensed healthcare provider to receive the results of the patch monitor.
  • SHD Cohort:
  • Adults aged 40 or older at the time of the ECG.
  • ECG obtained as part of a clinical care between study start date and the end of study recruitment
  • Patient is able to identify a licensed healthcare provider to receive the results of the echocardiogram.

排除标准

  • Retrospective Phase:
  • Patients who have previously requested that their data not be involved in any secondary use application such as a research study.
  • Prospective Phase:
  • AF Cohort:
  • Any clinical or social factor that would prohibit completing the follow-up studies in a timely fashion.
  • Patient currently admitted to the hospital (at time of consent)
  • Permanent pacemaker or implanted cardiac defibrillator or implanted loop recorder.
  • History of atrial fibrillation or atrial flutter.
  • Cardiac surgery within 30 days prior to the index ECG
  • Cardiac surgery planned within the next 6 months.
  • Allergy to adhesive.
  • SHD Cohort:
  • Any clinical or social factor that would prohibit completing the follow-up studies in a timely fashion.
  • Patient currently admitted to the hospital (at time of consent).
  • History of SHD defined as any of the following: severe mitral regurgitation, severe tricuspid regurgitation, moderate or severe aortic stenosis, moderate or severe aortic regurgitation, moderate or severe mitral stenosis, left ventricular systolic dysfunction (LVEF ≤ 40%), or increased septal wall thickness > 15 mm.
  • Allergy to ultrasound gel.

结局指标

主要结局

Positive-predictive value (PPV) of the SHD device at six months

时间窗: 12 months

Structural heart disease will be defined as: * moderate or severe mitral stenosis, aortic regurgitation, or aortic stenosis * severe mitral or tricuspid regurgitation * LVEF ≤ 40% * Interventricular septal thickness \>15mm

Positive-predictive value (PPV) of the AF device at six months

时间窗: 12 months

AF will be defined by findings from the patch monitor, participant interview or the EHR-based phenotype definition and will be considered positive if a diagnosis occurs within 6 months of the index ECG.

次要结局

  • Positive-predictive value (PPV) of the SHD device at 12 months(18 months)
  • Positive-predictive value (PPV) of the AF device at 12 months(18 months)

研究者

发起方
Tempus AI
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Electrocardiogram-based Artificial... | 临床试验